Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Treatment-resistant schizophrenia: Is slower-than-recommended titration of clozapine beneficial?

Key clinical point: Slower-than-recommended titration of clozapine for treatment-resistant schizophrenia may not provide additional benefit with respect to the safety of clozapine continuation and shorter length of hospital stay.

Major finding: No significant association was seen between slower-than-recommended clozapine titration rate and clozapine continuation for the first 18 weeks (adjusted odds ratio [aOR], 1.23; P = .78), fever occurrence within the first 4 weeks (aOR, 1.42; P = .58), and the cumulative rate of discharge within the first 12 months after clozapine initiation (aOR, 1.61; P = .29).

Study details: The data come from a retrospective study of 152 inpatients with treatment-resistant schizophrenia who were newly started on clozapine.

Disclosures: The study did not receive any funding. The lead author had no disclosures.

Citation:

Tsukahara M et al. Psychiatr Q. 2020 Sep 5. doi: 10.1007/s11126-020-09841-3.